{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emtricitabine%2Ftenofovir+%28FTC%2FTDF+%28Truvada%C2%AE%29%29&page=2",
    "query": {
      "intervention": "Emtricitabine/tenofovir (FTC/TDF (Truvada®))",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emtricitabine%2Ftenofovir+%28FTC%2FTDF+%28Truvada%C2%AE%29%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emtricitabine%2Ftenofovir+%28FTC%2FTDF+%28Truvada%C2%AE%29%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T00:09:17.671Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01772823",
      "title": "An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "3MV",
          "type": "BEHAVIORAL"
        },
        {
          "name": "PCC",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Emtricitabine/tenofovir (FTC/TDF (Truvada®))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "22 Years",
        "sex": "MALE",
        "summary": "18 Years to 22 Years · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2012-11",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772823"
    },
    {
      "nct_id": "NCT06101329",
      "title": "Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pre-Exposure Prophylaxis of HIV Infection"
      ],
      "interventions": [
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Injection",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 253,
      "start_date": "2023-11-17",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06101329"
    },
    {
      "nct_id": "NCT01769456",
      "title": "An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "PCC",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Emtricitabine/tenofovir (FTC/TDF (Truvada®))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "15 Years to 17 Years · Male only"
      },
      "enrollment_count": 78,
      "start_date": "2013-03",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769456"
    },
    {
      "nct_id": "NCT03472963",
      "title": "Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Single dose of Genvoya® and a single 800 mg dose of Darunavir®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "MALE",
        "summary": "18 Years to 49 Years · Male only"
      },
      "enrollment_count": 35,
      "start_date": "2018-04-27",
      "completion_date": "2019-03-29",
      "has_results": false,
      "last_update_posted_date": "2020-08-28",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472963"
    },
    {
      "nct_id": "NCT03502005",
      "title": "Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "bictegravir/emtricitabine/tenofovir alafenamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Midland Research Group, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2018-03-01",
      "completion_date": "2019-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 1,
      "location_summary": "Oakland Park, Florida",
      "locations": [
        {
          "city": "Oakland Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03502005"
    },
    {
      "nct_id": "NCT00752856",
      "title": "Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Kaletra + Isentress",
          "type": "DRUG"
        },
        {
          "name": "Atripla",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2008-08-26",
      "completion_date": "2014-02-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-22",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 6,
      "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 3 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752856"
    },
    {
      "nct_id": "NCT03110380",
      "title": "Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "DTG Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 567,
      "start_date": "2017-06-12",
      "completion_date": "2021-02-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 66,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110380"
    },
    {
      "nct_id": "NCT01869634",
      "title": "Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Infection"
      ],
      "interventions": [
        {
          "name": "darunavir with ritonavir and fixed-dose viread+emtricitabine daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2013-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01869634"
    },
    {
      "nct_id": "NCT00708162",
      "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Elvitegravir",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "EVG placebo",
          "type": "DRUG"
        },
        {
          "name": "RAL placebo",
          "type": "DRUG"
        },
        {
          "name": "Background regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 724,
      "start_date": "2008-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-30",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 94,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708162"
    },
    {
      "nct_id": "NCT01769469",
      "title": "Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "FTC/TDF (Truvada®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "22 Years",
        "sex": "MALE",
        "summary": "15 Years to 22 Years · Male only"
      },
      "enrollment_count": 101,
      "start_date": "2012-11",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-10-12T00:09:17.671Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769469"
    }
  ]
}